DBV Technologies | DBVT - Cash And Equivalent


DBV Technologies reported $174.9M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 956.47M 105.02M Jun/2026
Alnylam Pharmaceuticals USD 1.71B 2.46M Jun/2026
Amarin USD 143.56M 12.5M Jun/2026
BioCryst Pharmaceuticals USD 154.97M 16.62M Jun/2026
BioMarin Pharmaceutical USD 874M 1.35B Jun/2026
DBV Technologies USD 174.9M 54.3M Jun/2026
Galectin Therapeutics USD 25.6M 2.04M Jun/2024
Halozyme Therapeutics USD 163.14M 146.61M Jun/2026
Incyte USD 3.98B 33.45M Jun/2026
Insmed USD 544.76M 37.42M Jun/2026
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
Neurocrine Biosciences USD 332.4M 65.9M Jun/2026
PTC Therapeutics USD 1.05B 215.9M Jun/2026
Sarepta Therapeutics USD 571.15M 106.7M Jun/2026
Ultragenyx Pharmaceutical USD 125M 50M Jun/2026
United Therapeutics USD 1.8B 523.5M Jun/2026